---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-26-000121"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-09-16T20:32:09+00:00"
generated_at: "2026-09-16T20:33:05.993167+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Halozyme announces $1.05B convertible notes offering due 2033

## Summary
- Offering of $1.05B aggregate principal of convertible senior notes due 2033, unsecured, semi-annual interest, maturing Oct 1, 2033.
- 13-day option for initial purchasers to buy up to $150M additional notes, for potential total of $1.2B.
- Proceeds to fund capped call transactions, repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes, and general corporate purposes.
- Capped calls intended to reduce dilution; concurrent note repurchases may affect common stock price.

## SEC filing metadata
- accession: 0001159036-26-000121
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-09-16T20:32:09+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000121/0001159036-26-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000121/halo-20260916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-26-000121
- JSON: https://secwatch.observer/filing/0001159036-26-000121.json
- Plain text: https://secwatch.observer/filing/0001159036-26-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.